Caloric restriction mimetics (CRMs) are a class of compounds designed to replicate the health and longevity benefits of caloric restriction (CR)—reducing food intake without malnutrition—without requiring actual dietary restriction. Because long-term CR is difficult for humans to sustain and carries risks like muscle loss, CRMs represent a pharmacological strategy to delay biological aging and prevent age-related diseases.
Mechanisms of Action
CRMs work by tricking cells into a state of "perceived" nutrient scarcity, triggering conserved stress-response pathways usually activated by fasting.
• Autophagy Induction: A primary mechanism of CRMs is the stimulation of autophagy, the cellular "cleanup" process that recycles damaged proteins and organelles.
• Protein Deacetylation: CRMs often promote the deacetylation of cellular proteins by depleting acetyl-CoA or inhibiting acetyltransferases (like EP300), mimicking the biochemical environment of starvation.
• Key Signaling Pathways: They modulate master metabolic regulators:
◦ AMPK Activation: CRMs activate AMPK, the cell's energy sensor, which promotes fat burning and repair processes.
◦ mTOR Inhibition: They inhibit the mTOR pathway (specifically mTORC1), which normally drives growth; suppressing it shifts cells toward maintenance and repair.
◦ Sirtuin Activation: They activate sirtuins (e.g., SIRT1, SIRT3), enzymes that protect against oxidative stress and genomic instability.
Major Candidates
CRMs include both natural dietary compounds and synthetic drugs:
• Natural Agents:
◦ Spermidine: A polyamine found in wheat germ and aged cheese. It induces autophagy by inhibiting EP300 and is linked to improved cognition and cardiovascular health.
◦ Resveratrol: A polyphenol in red wine that activates SIRT1. While it improves metabolic health in obese mice, its ability to extend lifespan in healthy mammals remains debated.
◦ Quercetin & Fisetin: These act as senolytics, selectively eliminating senescent ("zombie") cells that accumulate with age and drive inflammation.
◦ Glucosamine: An amino sugar that inhibits glycolysis (glucose metabolism), inducing mitochondrial "hormesis" (beneficial stress) and extending lifespan in rodents and nematodes.
• Synthetic Agents:
◦ Metformin: A diabetes drug that activates AMPK. While it extends healthspan in disease models, recent large meta-analyses suggest it may not consistently extend lifespan in healthy vertebrates compared to rapamycin or CR.
◦ Rapamycin: An mTOR inhibitor that robustly extends lifespan across species (yeast to mice). However, its use in humans is complicated by side effects like immunosuppression, leading researchers to explore intermittent dosing protocols.
Current Status
While CRMs show profound effects in animal models, human evidence is largely limited to short-term trials or epidemiological associations. The ongoing TAME (Targeting Aging with Metformin) trial aims to provide clinical proof that a drug can delay multiple age-related diseases simultaneously in humans. Research suggests that cyclical use of these compounds (pulsing stress and recovery) may be superior to chronic use, preventing adaptation and side effects.
